CONMED (NASDAQ:CNMD) had its price target upped by Leerink Swann from $60.00 to $64.00 in a research note issued to investors on Tuesday. The firm currently has an outperform rating on the stock. Several other analysts have also recently commented on the stock. Analysts at Northland